Literature DB >> 21165208

Role of CD4CD25FOXP3 Regulatory T Cells in Psoriasis.

Woo-Jin Yun1, Deok-Woo Lee, Sung-Eun Chang, Ghil-Suk Yoon, Joo-Ryung Huh, Chong-Hyun Won, Mi-Woo Lee, Sung-Eun Kim, Beom-Joon Kim, Kee-Chan Moon, Jee-Ho Choi.   

Abstract

BACKGROUND: CD4(+)CD25(high+)regulatory T cells (Tregs) are considered to be of vital importance for maintaining immunologic self-tolerance and preventing autoimmune diseases. These cells have been found to be deficient in skin lesions and in the peripheral blood of patients with psoriasis.
OBJECTIVE: To investigate the role of Tregs in the pathogenesis of psoriasis and to evaluate the changes in Tregs in relation to the severity and the clinical course of psoriasis.
METHODS: Immunohistochemistry (CD3, 4, 8, 79 and FOXP3) was performed in 22 psoriatic patients compared to 5 normal controls. Flow cytometry (CD3, 4, 8, 25 and FOXP3) was performed in 18 psoriatic patients and 8 normal volunteers and reverse transcriptase polymerase chain reaction (foxp3 mRNA) was performed in 8 psoriasis patients.
RESULTS: An increase in the FOXP3(+) cell fraction was detected in the lesional psoriatic skin irrespective of the severity of psoriasis as compared with the normal skin. However, a decrease in FOXP3(+) cells was observed in the samples obtained from psoriasis of 'acute course'. FOXP3(+) Treg populations in the blood of the 'acute course' psoriasis was not different compared to that of 'chronic course' psoriasis and normal controls.
CONCLUSION: The deficiency of FOXP3(+) Tregs in the lesional psoriatic skin might be responsible for the exacerbation of psoriasis.

Entities:  

Keywords:  CD4+CD25high+regulatory T cells; FOXP3; Psoriasis

Year:  2010        PMID: 21165208      PMCID: PMC2991715          DOI: 10.5021/ad.2010.22.4.397

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  19 in total

Review 1.  Immune regulation by CD4+CD25+ regulatory T cells: implications for transplantation tolerance.

Authors:  Leonie Taams; Milica Vukmanovic-Stejic; Mike Salmon; Arne Akbar
Journal:  Transpl Immunol       Date:  2003 Jul-Sep       Impact factor: 1.708

2.  Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro.

Authors:  Subhasis Chattopadhyay; Shikhar Mehrotra; Arvind Chhabra; Upendra Hegde; Bijay Mukherji; Nitya G Chakraborty
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 3.  CD4+CD25+ regulatory T cells in health and disease.

Authors:  Haiying Liu; Bernard P Leung
Journal:  Clin Exp Pharmacol Physiol       Date:  2006 May-Jun       Impact factor: 2.557

4.  Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.

Authors:  Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

5.  Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.

Authors:  Jun Shimizu; Sayuri Yamazaki; Takeshi Takahashi; Yasumasa Ishida; Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

6.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late.

Authors:  W H P M Vissers; C H M Arndtz; L Muys; P E J Van Erp; E M G de Jong; P C M van de Kerkhof
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

8.  TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.

Authors:  Song Guo Zheng; Ju Hua Wang; William Stohl; Kyoung Soo Kim; J Dixon Gray; David A Horwitz
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

9.  Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.

Authors:  S Read; V Malmström; F Powrie
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  13 in total

1.  Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.

Authors:  Emiliano Antiga; Walter Volpi; Elisa Cardilicchia; Laura Maggi; Lucia Filì; Cinzia Manuelli; Paola Parronchi; Paolo Fabbri; Marzia Caproni
Journal:  J Clin Immunol       Date:  2012-06-15       Impact factor: 8.317

2.  Immunohistochemistry: relevance in dermatology.

Authors:  Aparna Palit; Arun C Inamadar
Journal:  Indian J Dermatol       Date:  2011-11       Impact factor: 1.494

Review 3.  Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

Authors:  Zhussipbek Mukhatayev; Yekaterina O Ostapchuk; Deyu Fang; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2021-01-18       Impact factor: 17.390

Review 4.  Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.

Authors:  Carolina Obregon; Rajesh Kumar; Manuel Antonio Pascual; Giuseppe Vassalli; Déla Golshayan
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

Review 5.  The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part II: The Treg role in skin diseases pathogenesis.

Authors:  Bogusław Nedoszytko; Magdalena Lange; Małgorzata Sokołowska-Wojdyło; Joanna Renke; Piotr Trzonkowski; Michał Sobjanek; Aneta Szczerkowska-Dobosz; Marek Niedoszytko; Aleksandra Górska; Jan Romantowski; Justyna Czarny; Jarosław Skokowski; Leszek Kalinowski; Roman Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

6.  The Plasticity of CD4+CD25+FOXP3+CD127low T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy.

Authors:  Maria S Sayapina; Svetlana N Bykovskaia
Journal:  J Oncol       Date:  2018-05-02       Impact factor: 4.375

7.  Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy.

Authors:  Chao Chen; Lirong Tan; Wu Zhu; Li Lei; Yehong Kuang; Panpan Liu; Jie Li; Xiang Chen; Cong Peng
Journal:  Mediators Inflamm       Date:  2020-06-28       Impact factor: 4.711

8.  Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8+ T cell response.

Authors:  Krista Stockenhuber; Ahmed N Hegazy; Nathaniel R West; Nicholas E Ilott; Alexander Stockenhuber; Samuel J Bullers; Emily E Thornton; Isabelle C Arnold; Andrea Tucci; Herman Waldmann; Graham S Ogg; Fiona Powrie
Journal:  J Exp Med       Date:  2018-07-06       Impact factor: 14.307

9.  Evaluation of selected mechanisms of immune tolerance in psoriasis.

Authors:  Agnieszka Owczarczyk-Saczonek; Joanna Czerwińska; Małgorzata Orylska; Waldemar Placek
Journal:  Postepy Dermatol Alergol       Date:  2019-06-19       Impact factor: 1.837

10.  Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.

Authors:  Agnes Szentpetery; Eric Heffernan; Martina Gogarty; Lisa Mellerick; Janet McCormack; Muhammad Haroon; Musaab Elmamoun; Phil Gallagher; Genevieve Kelly; Aurelie Fabre; Brian Kirby; Oliver FitzGerald
Journal:  Arthritis Res Ther       Date:  2017-07-05       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.